Mindfulness apps, mood trackers, and virtual therapy platforms are all designed to support mental health. However, as these technologies evolve, the line between wellness support and clinical treatment is becoming increasingly difficult to discern. And for psychologists exploring or recommending mental health technologies, understanding this distinction is essential.
The FDA’s guidance on Mobile Medical Applications provides a framework for differentiating between wellness tools and technologies that are considered therapeutic interventions. According to the FDA, a mobile app becomes a regulated medical device when it is intended to diagnose, treat, cure, mitigate, or prevent a disease or condition. In the context of mental health, this includes apps that, for example, deliver cognitive behavioral therapy for anxiety or provide exposure therapy for PTSD.
By contrast, apps that promote general wellness, such as mindfulness or relaxation tools, are typically not regulated by the FDA as long as they make no specific claims about treating a diagnosable mental health condition. The FDA views an app that helps users track their moods to better understand emotional patterns differently from an app that tailors interventions for depression based on the level of severity that a patient reports.
The key here is intended use. The FDA evaluates a product based on what it claims to do and how it positions itself in the marketplace. If an app presents itself as a treatment for a mental health disorder, it must be backed by scientific evidence and meet regulatory standards for safety, effectiveness, and data handling. These apps fall under the FDA’s oversight as Software as a Medical Device.
Why should this matter to us as psychologists? First, recommending or integrating a therapeutic app into care requires due diligence. If an app is marketed as a treatment, we need to ask: Is it FDA-cleared or approved? What clinical evidence supports its use? Does it comply with standards for data privacy and security?
